Q1 Earnings Forecast for FDMT Issued By HC Wainwright

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Investment analysts at HC Wainwright issued their Q1 2026 EPS estimates for 4D Molecular Therapeutics in a report issued on Wednesday, November 12th. HC Wainwright analyst M. Caufield expects that the company will earn ($1.05) per share for the quarter. The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for 4D Molecular Therapeutics’ Q2 2026 earnings at ($1.05) EPS, Q3 2026 earnings at ($1.05) EPS and Q4 2026 earnings at ($1.05) EPS.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its earnings results on Monday, November 10th. The company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.02) by $0.01. The company had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.40 million. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%.

A number of other equities research analysts also recently weighed in on the company. Morgan Stanley raised 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, October 8th. Leerink Partners reissued an “outperform” rating and set a $17.00 target price on shares of 4D Molecular Therapeutics in a research note on Friday, October 31st. Roth Capital dropped their target price on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating for the company in a report on Tuesday, August 12th. Finally, Chardan Capital lifted their price target on shares of 4D Molecular Therapeutics from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $28.70.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ:FDMT opened at $10.28 on Thursday. 4D Molecular Therapeutics has a 1 year low of $2.23 and a 1 year high of $12.34. The stock has a market capitalization of $587.30 million, a price-to-earnings ratio of -2.74 and a beta of 2.96. The company’s 50 day simple moving average is $9.25 and its 200 day simple moving average is $6.21.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP increased its position in shares of 4D Molecular Therapeutics by 3.7% during the third quarter. Dimensional Fund Advisors LP now owns 58,006 shares of the company’s stock worth $504,000 after buying an additional 2,069 shares during the period. Russell Investments Group Ltd. grew its holdings in 4D Molecular Therapeutics by 11.7% during the 2nd quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company’s stock worth $81,000 after acquiring an additional 2,284 shares during the period. Farther Finance Advisors LLC raised its position in shares of 4D Molecular Therapeutics by 117.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock worth $43,000 after acquiring an additional 2,674 shares in the last quarter. Peapod Lane Capital LLC lifted its stake in shares of 4D Molecular Therapeutics by 1.1% in the 3rd quarter. Peapod Lane Capital LLC now owns 322,081 shares of the company’s stock valued at $2,799,000 after purchasing an additional 3,544 shares during the period. Finally, Dynamic Technology Lab Private Ltd lifted its stake in shares of 4D Molecular Therapeutics by 35.6% in the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 16,369 shares of the company’s stock valued at $61,000 after purchasing an additional 4,295 shares during the period. 99.27% of the stock is owned by institutional investors.

Insider Buying and Selling at 4D Molecular Therapeutics

In other news, insider Scott Bizily sold 2,678 shares of the company’s stock in a transaction that occurred on Friday, October 24th. The stock was sold at an average price of $12.00, for a total value of $32,136.00. Following the completion of the transaction, the insider owned 3,594 shares of the company’s stock, valued at $43,128. This represents a 42.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders sold 9,128 shares of company stock worth $92,100 in the last quarter. Insiders own 9.60% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.